Compare BG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BG | ILMN |
|---|---|---|
| Founded | 1818 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 20.4B |
| IPO Year | 2023 | 2000 |
| Metric | BG | ILMN |
|---|---|---|
| Price | $124.51 | $122.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 17 |
| Target Price | ★ $130.29 | $124.24 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | 4.91 | ★ 5.45 |
| Revenue | ★ $70,329,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | $34.76 | $6.52 |
| Revenue Next Year | $1.62 | $5.49 |
| P/E Ratio | $25.77 | ★ $22.20 |
| Revenue Growth | ★ 32.43 | N/A |
| 52 Week Low | $71.60 | $68.70 |
| 52 Week High | $128.46 | $155.53 |
| Indicator | BG | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 46.25 |
| Support Level | $111.01 | $114.88 |
| Resistance Level | $124.78 | $135.68 |
| Average True Range (ATR) | 3.56 | 4.25 |
| MACD | 0.23 | 0.03 |
| Stochastic Oscillator | 76.40 | 37.31 |
Bunge Global SA is an agribusiness solutions company, connecting farmers to consumers and delivering essential food, feed and fuel to the globe. The company segments include Soybean Processing and Refining; Softseed Processing and Refining; Other Oilseeds Processing and Refining; Grain Merchandising and Milling; and Corporate and Other. It generates maximum revenue from the Soybean Processing and Refining segment, which includes integrated business principally involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of soybeans and soybean related products, as well as biodiesel and fertilizer production and distribution. Geographically, the company operates in United States, Switzerland, Netherlands, and Rest of the World.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.